

From the assay the absorbance of the Positive Control is : **0.985**

- The absorbance is found on the Y-axis;
- The line is followed to the standard curve;
- From the curve the line is followed to the X-axis to locate the EU/mL for the sample.
- The value for the Control in this example is: **67 EU/mL**

- Dilution of Serum
 Samples which give absorbances above the top Calibrator (320 EU/mL) are out of range of this assay, and should be stated as >320 EU/mL. Such samples may be diluted as appropriate. A further dilution of 1:5 is recommended. When calculating the results for a diluted sample, the concentration obtained must be corrected by the dilution factor (X 5).

EIA Software Program:

If using an EIA reader with the appropriate software for data reduction, choose log/lin for X/Y axis and point-to-point or equivalent as your choice for a curve fitting program.

NOTE: Assigned values for the Calibrators are expressed as EU/ml and are located on the label

INTERPRETATION OF RESULTS

Antibody EU/ml values are reported as a decimal number (10.2 EU/ml). The numeric value should be used

Positive = Equal to or greater than 15 EU/mL.

Equivocal = 5.1 – 14.9 EU/mL

Negative = Equal to or less than 5 EU/mL

If an equivocal result is obtained, re-test the sample. If upon repeat, the sample remains equivocal, it can be assumed that there is not a significant level of antibodies present in the sample to be classified as a definitive positive. The sample should be reported as equivocal and evaluated by the physician in the context of the patient's overall history.

QUALITY CONTROL

Positive and negative controls are supplied with the kit. The controls verify test performance, test integrity and operator reliability. Good laboratory practice dictates running the positive and negative controls each time the kit is used. If a result within the confidence limit (as listed on the label) of the positive and negative control is not obtained, test results are not valid.

If a repeat assay is performed, always use fresh dilutions of each Control and patient sample, regardless of when dilution was made.

If sufficient results cannot be obtained, contact the SCIMEDX Technical Service Department.

LIMITATIONS

- The antibody titer obtained from individual samples does not necessarily correlate with disease severity and should not be reported as such. Antibodies from different patients may have different avidities. Paired sera run at the same time under the same conditions will give a better indication of the disease process. However, the result of an assay is not diagnostic proof of the presence or absence of vasculitic disease and immunosuppressive therapy or treatment should not be started on a positive result.
- The values obtained from this assay are intended to be an aid to diagnosis only. Each physician must interpret the results in light of the patient's history, physical findings and other diagnostic procedures. Low positive samples should be evaluated in light of clinical symptoms and results of testing for other autoimmune antibodies, such as SLE, MPO, GBM, etc. Confirmation of results is advised by redrawing and retesting the patient.
- Discrepancies between IFA and EIA methodologies may be due to the fact that ANCA antigens contain additional specificities such as cathepsin, lactoferrin and elastase. Due to sequence similarities some cross-reactivity is possible. In addition, a small number of SLE patients, especially SLE with neurologic disease, will have

antibodies to myeloid elastase, cathepsin and lactoferrin.(16,17) In certain diseases (UC and/or PSC), a similar ANCA pattern has been identified but does not react with PR3 in ELISA. (18,19)

- If IFA is used as a screen, and atypical ANCA patterns are observed, these should be considered "suspect" and further testing by EIA is recommended.
- Only if test instructions are rigidly followed will optimum results be achieved.
- Use fresh serum or samples frozen only once and thawed. Samples that are improperly stored or are subjected to multiple freeze-thaw cycles may yield spurious results.
- Reproducible results depend on careful pipetting, observation of incubation periods and temperature, as well as rinsing the test strips and thorough mixing of all prepared solutions.
- Do not scratch coated wells during washing and aspiration. Dispense and fill all reagents without interruption. While dispensing, check that all wells are filled evenly with Wash solution and that there are no residues in the wells.
- Instructions for using appropriate photometers are to be observed; check adjustment of proper wavelength and reference wavelength respectively.
- Proper washing of the microwells is critical for reducing the potential of nonspecific reactions or residues causing false positive reactions. The use of automated washing equipment may require 4-5 rinses for each washing step.

EXPECTED RESULTS

Published clinical studies have demonstrated that <1% of patients suspected of having a vasculitis and/or glomerulonephritis resulted in a positive ANCA pattern. The specific autoantigen associated with C-ANCA was identified in 1990 as proteinase 3, a 29kD neutrophil serine protease of the azurophilis.(7,8,20) This finding had previously been characterized by Kao in 1988, confirming proteinase 3 as the primary antigen in Wegener's. (8,21)

The presence of C-ANCA antibodies is associated with many different vasculitic disease states with classic Wegener's resulting in a sensitivity range of > 90%. Classic or extended Wegener's has been characterized by granulomatous inflammation of the respiratory tract, necrotizing crescentic glomerulonephritis and systemic vasculitis. Patients with more benign disease such as pauci-immune necrotizing glomerulonephritis are detected approximately 40-50% of the time. In patients with limited Wegener's without renal involvement the rate of detection is 67-86%.(22-25)

It should be noted that not all C-ANCA positive sera will react with PR3 antigen. Depending on the methods and antigens used in the test, the sensitivity range is approximately 70-100%. Positive C-ANCA sera may contain additional antibodies that are not present in the PR3 antigen.(22-25) Characterization of additional target antigens in ANCA related diseases will play an important role in future antigen designations and their relationship to specific disease states. For now the detection of PR3 antibodies and subsequent identification of patients with Wegener's has proven to be a valuable diagnostic tool.

The following table shows the incidence of PR3 antibodies in the various disease state sera obtained from clinical studies performed in the evaluation of anti-PR3 Antibody in human serum:

Disease State	Total	PR3 Neg	PR3 Pos
MPO	36	33	3
UC	21	20	1
ICGN	25	20	5
WG	26	11	15
CGN	4	3	1
MPA	18	18	0
PAN	2	1	1
PRS	4	3	1
ATN	1	1	0
other Autoimmune	10	8	2
other Vasculitic	3	2	1

MPO = Myeloperoxidase; UC = Ulcerative Colitis; ICGN = Idiopathic Crescentic Glomerulonephritis; WG = Wegeners; CGN = Crescentic Glomerulonephritis; MPA = Microscopic Polyarteritis; PAN = Polyarteritis Nodosa; PRS = Pulmonary Renal Syndrome; ATN = Acute Tubular Necrosis.

PERFORMANCE CHARACTERISTICS

Comparison

A study was performed using 204 patient samples that were clinically characterized as ANCA positive or negative, 80 patient samples positive for other autoimmune disease state markers, and 216 normals from a blood bank. These assays were assayed in the Scanlisa anti-PR3 kit and the results compared to a reference Scimedx anti-PR3 kit. Of the 204 samples, 18 were also tested by c-ANCA IFA. The results yielded a sensitivity of 97.9%, a specificity of 99.5%, and an agreement of 96.4% compared to the reference EIA kit when equivocal samples were counted as negative.

Eighteen samples were tested by EIA and IFA. Of the 16 samples that were positive in the reference EIA and negative in the Scanlisa kit, 14 of these were negative by IFA. Of the 2 samples that were positive in the Scanlisa kit and negative in the reference EIA, both were negative by IFA.

NHS	Reference	Scanlisa
Positive	0	0
Negative	216	197
Equivocal	0	19
Total	216	216

Relative Specificity = 100%

Relative Agreement = 100%

Autoimmune	Reference	Scanlisa
Positive	0	0
Negative	80	68
Equivocal	NA	12
Total	80	80

Relative Specificity = 100%

Relative Agreement = 100%

Positive	Reference	Scanlisa
Positive	109	95
Negative	95	85
Equivocal	NA	24
Total	204	204

Relative Sensitivity = 97.9%

Relative Specificity = 98.2%

Relative Agreement = 91.2%

Reproducibility

Five sera (3 positive, 1 equivocal and 1 negative) were run in 16 replicates for **Intra-Run** reproducibility. The following EU/mL results were obtained:

	Serum 1	Serum 2	Serum 3	Serum 4	Serum 5
MEAN	285.5	89.7	53.6	8.9	2.2
S.D.	39.9	10.1	2.1	0.4	0.1
% C.V.	14.0	11.2	3.9	4.5	3.2

Five sera (4 positive and 1 negative) were run on 3 lots of anti-PR3 kits in two runs to evaluate the **Inter-Lot** reproducibility. The following EU/mL results were obtained:

	Serum 1	Serum 2	Serum 3	Serum 4	Serum 5
MEAN	276.3	119.9	59.3	7.9	2.2
S.D.	35.8	16.1	4.6	0.9	0.1
% C.V.	13.0	13.4	7.8	11.2	6.7

Five sera (3 positive, 1 equivocal, and 1 negative) were run on 5 separate days in duplicate to evaluate the **Inter-Day** reproducibility. The following EU/mL results were obtained:

	Serum 1	Serum 2	Serum 3	Serum 4	Serum 5
MEAN	323.7	113.3	39.2	21.9	2.4
S.D.	26.0	9.9	7.7	1.4	0.5
%C.V.	8.0	8.7	19.7	6.6	19.5

BIBLIOGRAPHY

- Wegener, F., The histopathological definition of Wegener's granulomatosis, In: APMIS Suppl. 19, 98, , p 13, 14, 1990
- Faber, V., Elling, P., Norup, G., et.al., An antinuclear factor specific for leucocytes, Lancet 2:344-345, 1964
- Davies, D.J., Moran, J.E., Niall, J.F., et.al., Segmental necrotizing glomerulonephritis with antineutrophil antibody: possible arbovirus etiology, Br. Med. J., 285:606, 1982
- Hall, J.B., Wadham, BMCN, Wood, C.F., et.al., Vasculitis and glomerulonephritis: a subgroup with an antineutrophil cytoplasmic antibody, Aust. NZ J. Med., 14:277-278, 1984
- Van der Woude, F.J., Rasmussen, N., Lobatto, S., et al: Autoantibodies against neutrophils and monocytes: Tool for diagnosis and marker of disease activity in Wegener's granulomatosis, Lancet, 2: 425-429, 1985
- Wieslander, J., How are antineutrophil cytoplasmic autoantibodies detected?, Am. J. Kidney Diseases, Vol XVIII, No. 2 (Aug.), pp 154-158, 1991
- Goldschmeding, R., et al: The relation of 29 kD C-ANCA antigen to proteinase 3, In: APMIS, Suppl 19, 98: pp.26-27, 1990
- Cohen Tervaert, J.W., J.D. Elema, and C.G.M. Kallenberg, Clinical and histopathological association of 29kD-ANCA and MPO-ANCA, APMIS Suppl. 19, 98, p 35, 1990
- Falk, R.J., Jennette, C.J., Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis, N. Engl. J. Med., 318: 1651-1657, 1988
- Falk, R.J., Hogan, S.L., Wilkman, A.S., Terrell, S., Lauritzen, S., Charles, L.A. and Jennette, J.C.: Myeloperoxidase specific anti-neutrophil cytoplasmic autoantibodies (MPO-ANCA), In: Neth J Med., , 36: pp. 121 - 125, 1990
- Daha, M.R. and Falk, R.J.: Anti-Myeloperoxidase antibodies and clinical associations, In: Neth J Med, 1990, 36: pp. 152-153.
- Cohen Tervaert, J.W., et.al., Association of autoantibodies to myeloperoxidase with different forms of vasculitis, Arthritis and Rheumatism, Vol. 33, No. 8 (Aug.) pp. 1264-1272, 1990
- Goldschmeding, R., et.al., Different immunological specificities and disease associations of c-ANCA and p-ANCA, Neth. J. of Med., 36: 114-116, 1990
- Wiik, A., Current classification and definition of autoantibodies to neutrophil granulocytes, APMIS, Suppl. 19, 98: 24-25, 1990

14. Saxena, R. & Wieslander, J., Differential diagnosis of reno-pulmonary syndrome using enzyme-linked immunosorbent assay, Europ. Clinical Lab, Apr. , 1991
15. Flesch, B.K., et.al., Anti-elastase, cathepsin G, and lactoferrin antibodies in sera with c-ANCA or atypical fluorescence staining pattern (Abstract), The 3rd International workshop on ANCA, Wash. D.C., 8, 1990
16. Lucena-Fernandes, M.F., et.al., Atypical ANCA in rheumatic diseases (Abstract), The 3rd International workshop on ANCA, Wash. D.C., 8, 1990
17. Hardarson, S., et.al., Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases, Clin. Micro. and Immunol., Vol. 99, No. 3: 277-281, 1992
18. Goeken, J.A., ANCA in inflammatory bowel and liver diseases: new evidence for an autoimmune etiology?, Clinical Immunol. Newsletter, Vol. 13, No. 9/10, 1993
19. Bygren, P., Rasmussen, N., Isaksson, B., & Wieslander, J., Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis, European J. of Clin. Investig., 22, pp 783-792, 1992
20. Ludemann, J., et.al., J. of Exp. Medicine, 171, pp 357-362, 1990
21. Kao, R.C., et.al., J. of Clin. Immun., 82, pp 1963-1973, 1988
22. Gross, W.L., 5th International ANCA Workshop, September, 1993
23. Callenberg, C.G., et.al., Amer. J. Medicine, 93, pp 675-681, 1992
24. Falk, R.J., et.al., Amer. J. Kidney Dis., Vol. XVIII, No. 2 (Aug.) pp 145-147, 1991
25. Nolle, B., et.al., Annals Intern. Med., pp 28-40, 1989

12. Do not let wells dry during assay; add reagents immediately after completing the rinsing steps.
13. Do not use reagents past their expiration date.
14. Do not reuse microwells and do not pour reagents back into vials as reagent contamination may occur.
15. Incubation times and temperatures other than those specified may give erroneous results.
16. No assurance is given that these reagents are free of microbial or fungal contamination.
17. If sodium hypochlorite (bleach) solution is being used as a disinfectant, do not expose to work area during actual test procedure because of potential interference with enzyme activity.
18. **CAUTION:** Liquid waste at acid pH must be neutralized prior to adding to sodium hypochlorite solutions (bleach) to avoid formation of poisonous gas.

STABILITY AND STORAGE

1. The kits should be stored at 2 - 8°C. Do not freeze.
2. Discoloration of the liquid Substrate ranging from light yellow to intense yellow indicates substrate deterioration and the material should not be used.
3. The Ready to Use Conjugate, Calibrators, and Controls are stable up to the expiration dates listed on the respective bottle labels when stored at 2-8°C. Never freeze the solutions.
4. Diluted 1X Wash Buffer remains stable for 60 days at 2 - 8°C.
5. After opening the foil pouch, microplates coated with the protein antigens should be resealed with the desiccant provided.

SERUM COLLECTION

A whole blood sample should be collected by qualified personnel using approved aseptic venipuncture techniques. Obtain and/or clarify serum samples containing visible particulate matter by centrifugation. The samples may be stored at 2 - 8°C if testing is to be done within 5 days. If stored longer, they should be frozen at -20°C or lower. Do not use a frost-free freezer which may allow the specimens to go through freeze-thaw cycles that can denature the IgG antibody and cause spurious results. Do not use hyperlipemic, hemolytic, heat treated or contaminated samples.

PREPARATION OF REAGENTS AND SAMPLES

1. Bring **all** reagents to room temperature before use. Remove the number of strips being used for the day's testing and replace the remainder in the foil pouch with desiccant at 2-8°C.
2. Sample Diluent (green): - Ready to use.
3. Calibrators (green): The Calibrators are ready to use and the assigned values are indicated on their labels. **Do not dilute further.**
4. Positive and Negative Controls: Ready to use. **Do not dilute further.**
5. Patient's Sera: Dilute each patient serum 1:50 with Sample Diluent. Prepare dilutions(10µL+ 0.490 mL in cluster tubes. Mix by inverting the tubes a few times or use vortex on a low speed.
6. Assign each well the appropriate sample. For better accuracy, duplicate wells for the Calibrators, Controls and samples may be run. Use well A-1 as a reagent blank if a reference wavelength of 620 nm is not available on the reader. This "blank" well should contain assay diluent, conjugate and substrate.
7. Conjugate (Ready to Use): **DO NOT dilute conjugate further.**
8. pNPP liquid Substrate: Ready to use.
9. Wash Buffer (10X): Dilute the buffer 1 + 9 using distilled or deionized water or by pouring total contents into a container and add distilled or deionized water to 1,000 ml final volume. Mix thoroughly and store the 1X solution at 2-8°C.
10. Stop Solution (1.2M NaOH): Ready to use

ASSAY PROCEDURE


1. Transfer 100 µL/well of Sample Diluent into well A-1 for Blank, if appropriate (see # 6 above). Transfer 100µL/well of each Calibrators, Controls and each diluted sample to the corresponding position in the microwell strips. Cover the microwells and incubate for **30** minutes at room temperature.
2. Rinse 3 times with 300 µL/well of 1X Wash Buffer. If rinsing is done manually, empty the plate by shaking into a suitable container and blotting inverted on a paper towel.
3. Dispense 100 µL of ready to use Conjugate into each well (including A-1) using a multichannel pipettor. Cover the microwells and incubate for **30** minutes at room temperature.
4. Rinse as described above in step # 2.
5. Add 100 µL of Substrate Solution to all wells using a multichannel pipettor. Cover the microwells and incubate at room temperature for **30** minutes.
6. Terminate the reaction by adding 100 µL of Stop Solution (1.2 m NaOH) to each well using a multichannel pipettor. Shake the plate for 10 –20 seconds to mix. Be careful not to splash the solution from the wells.
7. Results: Zero the reader on well A-1 and read the absorbance of the wells at 405 nm **or** use the reference wavelength of 620 nm in an appropriate microplate reader.
NOTE: The wavelength of microplate or strip reader used should be set at 405 nm. If a reference wavelength is not available, use a reagent blank consisting of diluent, conjugate, and substrate. The absorbance of the reagent blank (A-1) is automatically subtracted from each well before calculations are done. The absorbance at 405 nm of the samples, Controls and the Calibrators must always be determined at the same time. Do not subtract the absorbance value of the reagent blank (A-1) if a reference wavelength is used.

CALCULATION OF RESULTS

Calibrators:

1. This kit contains 4 vials of Calibrator autoantibody levels. A curve constructed from the concentration of the Calibrators versus their Absorbances is used to calculate the EU/ml of autoantibody in the tested specimen.
2. Since International Standards are not yet available for the whole range of SCIMEDX kits, the EU/ml given are calibrated using internal control sera. Where available, SCIMEDX provides kits which are calibrated in International Units according to internationally recognized standards.
3. Graph Method:
A. Plot the absorbance values for the Calibrators on the linear ordinate (Y axis) against the corresponding EU/ml on the logarithmic abscissa (X-axis) using log/lin graph paper.
Locate the point corresponding to the absorbance value (Y-axis) of each specimen and read its corresponding EU/ml from the X-axis.

Example: Using log/lin graph paper, the following standard curve is plotted:



INTENDED USE

The SCIMEDX Corporation Scanlisa Anti-Proteinase 3 (anti-PR3) Test is a semi-quantitative indirect enzyme immunoassay (EIA) for the *in vitro* diagnostic detection in human serum of autoantibodies specific for proteinase 3 (PR3) antigen. The test is intended as an aid in the diagnosis of Wegener's granulomatosis and to conditions associated with raised anti-neutrophil cytoplasmic antibodies (ANCA) and is not definitive in isolation. Autoantibody levels represent one parameter in a multicriterion diagnostic process.

CLINICAL SIGNIFICANCE

In 1939, Friedrich Wegener described a disease called "rhinogenic granulomatosis". Early in the disease granulomas are found that, like the rheumatic nodules, develop independently from the vessels in the connective tissue. During the generalized stage, one will usually find the granuloma in close relation to the vessels in different regions of the body, sometimes in only one, sometimes in all organs. The systemic vasculitis occurs later. The connective tissue diseases are associated with autoantibodies to various non-organ-specific antigens, particularly nuclear antigens.⁽¹⁾ Autoantibodies to neutrophils have been known for a long time. As early as 1964 a granulocyte-specific antinuclear factor was reported.⁽²⁾ The use of an ethanolic fixation technique for granulocyte-specific antinuclear antibodies (GS-ANA) is the standard today. The cytoplasmic staining of granulocytes was first published in 1982 in a report of Australian patients with segmental necrotizing glomerulonephritis.⁽³⁾

Four more patients were reported with vasculitis and glomerulonephritis.⁽⁴⁾

In 1985, van der Woude⁽⁵⁾ showed that the antineutrophil cytoplasmic autoantibodies (ANCA) occurred with Wegener's granulomatosis, as a result the interest in these antibodies significantly increased.⁽⁶⁾ These antibodies, now termed C-ANCA, have proven useful for the diagnosis of disease in systemic vasculitis. From the alpha granules, it is possible to isolate a protein with an estimated molecular weight of 29 kD. The N-terminal sequence of the 29 kD protein is now available from the work of several laboratories, and it is clear that the antigen is identical to a neutral serine proteinase called Proteinase 3. During the last few years, it has been recognized that Proteinase 3 is the important C-ANCA antigen associated with the diagnosis of Wegener's granulomatosis, since most patients have antibodies to Proteinase 3.⁽⁷⁾ These antibodies produce a characteristic granular cytoplasmic staining pattern in the cytoplasm of ethanol-fixed granulocytes and are directed against the 29 kD protein triplet from myeloid lysosomes with serine protease activity⁽⁸⁾.

In the immunofluorescence test for antineutrophil cytoplasmic antibodies, staining patterns that are different from the granular cytoplasmic pattern produced by the antibodies to the 29 kD serine protease have been recognized; in particular, a perinuclear pattern has been observed. This pattern is produced from antibodies against two other myeloid lysosomal enzymes - myeloperoxidase (MPO) and human leukocyte elastase. Falk and Jennette have identified MPO antibodies^(9,10) in patients with either idiopathic or vasculitis-associated crescentic glomerulonephritis. The presence of antibodies to MPO or Proteinase 3 have proven to be highly specific and sensitive for this group of disorders, and useful in the clinical analysis of patients suspected of having vasculitis.⁽¹¹⁻¹⁴⁾

Further identification and purification of the ANCA antigen has resulted in antibody detection by enzyme immunoassay for both MPO and PR3.⁽¹⁵⁾ Simultaneous testing for MPO and PR3 antibodies is recommended.⁽⁶⁾

PRINCIPLE OF THE TEST

Diluted sera are incubated in assigned wells and antibodies present in the specimen bind to the Proteinase 3 antigen on the wells. Unbound antibodies are rinsed off and a second incubation with goat antihuman IgG conjugated to the alkaline phosphatase enzyme follows. Unbound conjugate is rinsed off and the bound conjugate is visualized by incubation with pNPP substrate that turns yellow when degraded by the enzyme. After addition of the Stop Solution the reacted substrate turns yellow and the intensity of the developed color is recorded at 405 nm, and correlates directly with the titer of the anti-PR3 in the specimen. The whole assay can be performed in less than 2 hours.

KIT COMPONENTS

ITEM	CONTENTS	QUANTITY
1.	PR3 Antigen coated strips	12 X 8 wells / pouch
2.	Goat antihuman IgG conjugated to Alk. Phosphatase— Ready to Use	15 mL
3.	Calibrators: 320, 80, 20, 5 EU/mL	1 X 1.0 mL
4.	PR3 Positive Control – Ready to Use	1 X 1.0 mL
5.	PR3 Negative Control – Ready to Use	1 X 1.0 mL
6.	Sample Diluent - Ready To Use	1 X 75 mL
7.	Wash buffer (10X)	1 X 100 mL
8.	pNPP Substrate - Ready To Use	1 X 15 mL
9.	Stop Solution – Ready To Use	1 X 30 mL

NOTE: Liquid reagents contain Proclin 300™ as the preservative

MATERIALS REQUIRED BUT NOT PROVIDED

- Tube rack in a microplate configuration.
- Multichannel pipettor of 50 - 250 µL range, and micropipettors of 200 -1000 µL and 2 - 20 µL ranges, and Pipette tips.
- Graduated cylinder.
- Cover for microwells.
- Clean containers for diluted Wash Buffer.
- Reservoirs (disposable).
- Test tubes or cluster tubes.
- Lint free paper towels.
- Calibrated microplate reader adjusted to read at 405 nm.
- Timer (30 min. range).
- Distilled or deionized water.

PRECAUTIONS

1. **Caution:** All blood products should be treated as potentially infectious. Human source materials from which this product was derived were found to be nonreactive for Hepatitis-B surface antigen (HBsAg), HCV, and Human Immunodeficiency Virus (HIV) 1 & 2 antibody when tested in accordance with current FDA required tests. No known test methods can offer total assurance that products derived from human blood will not transmit HIV, Hepatitis or other potentially infectious agents. Therefore, these reagents and all patients' specimens should be handled at Biosafety Level 2 as recommended for any potentially infectious human serum or blood specimen in the CDC/NIH manual - "Biosafety in Microbiology and Biomedical Laboratories", 1984 or latest edition.
2. For *in vitro diagnostic use* only.
3. Reagents in this kit contain 0.1% Proclin 300 as a preservative.
4. All components in this kit have been tested and standardized as a unit. Do not intermix components from different kit lots or other manufacturer's kits.
5. All reagents must be at room temperature (21 - 26°C) before running the assay. Temperature WILL affect the absorbances of the assay, but will not change the EU values calculated from the standard curve.
6. Use only distilled or deionized water and clean glassware.
7. Stop Solution should be handled carefully as it can cause burns or irritation to the skin and eyes. If contact occurs, flush immediately with water.
8. Negative and Positive Controls, as well as the Calibrators, must be run with each assay.
9. Use separate pipette tips for each sample, control and reagent to avoid cross contamination.
10. Use reservoirs only for single reagents. This especially applies to the substrate reservoir. Using a reservoir for dispensing a substrate solution that had previously been used for the conjugate solution may turn the Substrate Solution yellow.
11. Mix the contents of the microplate wells thoroughly to ensure good test results.

Scanlisa anti-PR3 ANTIBODY

ENZYME IMMUNOASSAY FOR THE
DETECTION OF
ANTI-PROTEINASE 3 ANTIBODIES IN
PATIENT SERUM

For In Vitro Diagnostic Use

CATALOG NO.:
PR3396 96 Test

New
30/30/30 Format
Ready for Use

SCIMEDX
CORPORATION



Your Preferred
Autoimmune and
Infectious Disease
Detection Company

400 FORD ROAD
DENVER, NEW JERSEY 07834 U.S.A.
(973) 625-8822 ♦ FAX: (973) 625-8796

CUSTOMER INQUIRIES:
(800) 221-5598

 SCIMEDX CORPORATION
400 Ford Road
Denville, NJ 07834 USA
Tel: 800.221.5598 Tel: 973.625.8822
Fax: 973.625.8796
www.scimedx.com

EC	REP	Emergo Europe Molenstraat 15 2513 BH The Hague The Netherlands
----	-----	-------------------------------------------------------------------------



Printed in U.S.A. Rev. E, 12/31/03

PR3396.E